Shelly Kakar1, Mohannad Dugum2, Ricardo Cabello1, Abhinav Humar3, Jawad Ahmad4, Shahid M Malik5. 1. Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA. 2. Center for Liver Diseases, Division of Gastroenterology, Hepatology and Nutrition, Department of Medicine, University of Pittsburgh, 3471 5th Ave 916 Lillian Kaufman Building, Pittsburgh, PA, USA. 3. Division of Abdominal Transplant Surgery, Department of Surgery, University of Pittsburgh, Pittsburgh, PA, USA. 4. Division of Liver Diseases, Icahn School of Medicine at Mount Sinai, New York, NY, USA. 5. Center for Liver Diseases, Division of Gastroenterology, Hepatology and Nutrition, Department of Medicine, University of Pittsburgh, 3471 5th Ave 916 Lillian Kaufman Building, Pittsburgh, PA, USA. maliks@upmc.edu.
Abstract
BACKGROUND: Cirrhosis secondary to nonalcoholic steatohepatitis (NASH) is projected to become the leading indication for liver transplantation (LT) in the USA in the next decade. The long-term implications of post-LT NASH, specifically on the development of allograft cirrhosis, are not well known. METHODS: A retrospective cohort of patients at a single large center undergoing LT for NASH from 2000 to 2015 was identified using a prospectively collected database. A total of 226 patients undergoing LT for NASH were identified. Mean follow-up for the cohort was 7 years. Seventy-five percent of patients underwent at least one liver biopsy post-LT. RESULTS: Eighty-one patients (36%) developed recurrence of biopsy-proven NASH. Fifteen patients developed bridging fibrosis but only four patients (1.8%) progressed to recurrent NASH cirrhosis at a mean of 9 years post-LT. Body mass index at the time of LT was statistically higher in the NASH allograft cirrhosis group. Recurrent disease was less common and less severe in those transplanted with black donors. All four patients with recurrent NASH cirrhosis developed evidence of portal hypertension, but all remained alive at follow-up. CONCLUSION: Although recurrent NASH following LT is common, the development of allograft cirrhosis is rare. These findings are useful when counseling patients and important to consider during their post-LT care.
BACKGROUND:Cirrhosis secondary to nonalcoholic steatohepatitis (NASH) is projected to become the leading indication for liver transplantation (LT) in the USA in the next decade. The long-term implications of post-LT NASH, specifically on the development of allograft cirrhosis, are not well known. METHODS: A retrospective cohort of patients at a single large center undergoing LT for NASH from 2000 to 2015 was identified using a prospectively collected database. A total of 226 patients undergoing LT for NASH were identified. Mean follow-up for the cohort was 7 years. Seventy-five percent of patients underwent at least one liver biopsy post-LT. RESULTS: Eighty-one patients (36%) developed recurrence of biopsy-proven NASH. Fifteen patients developed bridging fibrosis but only four patients (1.8%) progressed to recurrent NASH cirrhosis at a mean of 9 years post-LT. Body mass index at the time of LT was statistically higher in the NASH allograft cirrhosis group. Recurrent disease was less common and less severe in those transplanted with black donors. All four patients with recurrent NASH cirrhosis developed evidence of portal hypertension, but all remained alive at follow-up. CONCLUSION: Although recurrent NASH following LT is common, the development of allograft cirrhosis is rare. These findings are useful when counseling patients and important to consider during their post-LT care.
Authors: Jennifer E Layden; Scott Cotler; Kimberly A Brown; Michael R Lucey; Helen S Te; Sheila Eswaran; Claus Fimmel; Thomas J Layden; Nina M Clark Journal: Transplantation Date: 2012-07-27 Impact factor: 4.939
Authors: Shahid M Malik; Michael E Devera; Paulo Fontes; Obaid Shaikh; Eizaburo Sasatomi; Jawad Ahmad Journal: Liver Transpl Date: 2009-12 Impact factor: 5.799
Authors: Sanjaya K Satapathy; Quynh T Tran; Alexander J Kovalic; Sai Vineela Bontha; Yu Jiang; Satish Kedia; Saradashri Karri; Vamsee Mupparaju; Pradeep S B Podila; Rajanshu Verma; Daniel Maluf; Valeria Mas; Satheesh Nair; James D Eason; Dave Bridges; David E Kleiner Journal: Clin Transl Gastroenterol Date: 2021-02-05 Impact factor: 4.488
Authors: Christopher J Mowry; Cristina Alonso; Marta Iruarrizaga-Lejarreta; Pablo Ortiz; Josh Levitsky; Mary Rinella Journal: Transplant Direct Date: 2021-11-05